AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Nona Biosciences and Alaya.bio Announce Collaboration to advance CAR-T Cell Therapy

NextEdge Admin

15 Jul 2024

2 min 13 sec

CAR T-Cell Therapy,Targeted Therapy,Next Generation Therapeutics,Precision Medicine

Nona Biosciences, a global biotechnology firm offering comprehensive solutions from target validation and antibody discovery through preclinical research, has entered into a collaboration with Alaya.bio, a biotechnology company pioneering a novel polymeric delivery platform. This partnership aims to streamline the development, manufacturing, and administration of CAR-T cell therapies.

The collaboration will harness Nona's HCAb Harbour Mice® platform and site-specific conjugation technology, combined with Alaya.bio's polymeric in situ delivery platform, to create CAR-T product candidates for clinical applications. Nona's fully human HCAbs, known for their compact size and precise binding properties, are ideal for next-generation biotherapeutics. Their site-specific conjugation technology preserves antibody function, enhancing the specificity and versatility of Alaya.bio's delivery systems.

In the initial phase, Nona will provide Alaya.bio with antibodies against multiple targets for use in Alaya.bio's in vivo CAR program. In the second phase, Alaya.bio will select binders to be conjugated onto their polymeric nanoparticles using Nona's technology, advancing their CAR product candidate towards clinical trials.

Dr. Jingsong Wang, Chairman of Nona Biosciences, expressed enthusiasm for the collaboration, anticipating the introduction of more promising CAR-T therapies. Renaud Vaillant, CEO & Co-founder of Alaya.bio, highlighted the importance of the high-quality targeting agents from Nona Biosciences, which ensure the efficacy and safety of their technology. Both leaders see this collaboration as a significant step forward in differentiating their offerings from existing solutions.